Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Desperately seeking genotype-selective anticancer agents.

John S Lazo1

  • 1Department of Pharmacology, University of Pittsburgh, Pittsburgh, PA 15232, USA.

Chemistry & Biology
|July 3, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting PTP4A3 with KVX-053 mitigates alcohol-amplified SARS-CoV-2 spike protein-induced acute lung injury.

Frontiers in pharmacology·2026
Same author

The PTP4A3 inhibitor KVX-053 reduces Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virulence, inflammation, and development of acute lung injury in K18-hACE2 mice.

Respiratory research·2025
Same author

KVX-053, a protein tyrosine phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 spike protein subunit 1-induced acute lung injury in mice.

The Journal of pharmacology and experimental therapeutics·2025
Same author

Deletion of PTP4A3 phosphatase in high-grade serous ovarian cancer cells decreases tumorigenicity and produces marked changes in intracellular signaling pathways and cytokine release.

The Journal of pharmacology and experimental therapeutics·2025
Same author

KVX-053, a Protein Tyrosine Phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 Spike protein subunit 1 - induced acute lung injury in mice.

The Journal of pharmacology and experimental therapeutics·2024
Same author

Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells.

Nature medicine·2024
Same journal

The Hedgehog Pathway Effector Smoothened Exhibits Signaling Competency in the Absence of Ciliary Accumulation.

Chemistry & biology·2017
Same journal

DIVERSE System: De Novo Creation of Peptide Tags for Non-enzymatic Covalent Labeling by In Vitro Evolution for Protein Imaging Inside Living Cells.

Chemistry & biology·2015
Same journal

Differential Regulation of Specific Sphingolipids in Colon Cancer Cells during Staurosporine-Induced Apoptosis.

Chemistry & biology·2015
Same journal

Synthetic Peptides as cGMP-Independent Activators of cGMP-Dependent Protein Kinase Iα.

Chemistry & biology·2015
Same journal

Unraveling the B. pseudomallei Heptokinase WcbL: From Structure to Drug Discovery.

Chemistry & biology·2015
Same journal

Vitamin C as Cancer Destroyer, Investigating Sulfhydration, and the Variability in CFTR Interactome.

Chemistry & biology·2015
See all related articles

Researchers have developed a novel method to find drugs that specifically target cancer cells with multiple genetic defects. This approach could revolutionize cancer therapy by focusing on tumor genetics instead of location.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Cancer treatment often relies on histology or anatomical location, which may not fully capture tumor heterogeneity.
  • Tumors with multiple genetic abnormalities present unique therapeutic challenges.
  • Targeting specific genetic defects offers a more precise approach to cancer therapy.

Purpose of the Study:

  • To describe a new strategy for identifying therapeutic agents.
  • To develop compounds that selectively eliminate mammalian cells with multiple genetic abnormalities.
  • To advance cancer treatment modalities based on tumor genotype.

Main Methods:

  • Development of a screening approach to identify novel therapeutic agents.
  • Focus on cellular targets with multiple genetic alterations.

Related Experiment Videos

  • Evaluation of compound selectivity for abnormal cells.

    • Main Results:

    • An approach has been established to identify selective cytotoxic agents.
    • The identified agents demonstrate potential for targeting cells with genetic abnormalities.
    • This method facilitates the discovery of genotype-specific cancer therapeutics.

    Conclusions:

    • The described approach enables the identification of novel cancer-killing agents.
    • This strategy supports the development of innovative cancer treatments.
    • Genotype-driven cancer therapy represents a promising future direction.